Skip to main content

Table 3 Detailed information of discordant cases for PD-L1 expression among paired samples

From: Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples

No. Specimen 1 Time interval Specimen 2
Type VTC Treatment Staining intensity PD-L1% Type VTC Treatment Staining intensity PD-L1%
1 Surgical resection (lung) 10,000 NT 3+ 70 18.5 m MPE 10,000 AITa 3+ 40
2 Subaxillary mass biopsy 790 CM, AIT 1+ 15 10.2 m MPE 10,000 CMa, AIT 3+ 90
3 CTG-CN (lung) 400 NT 1+ 45 5.1 m MPE 100,000 TGTa 3+ 90
4 CTG-CN (lung) 5000 NT 1+ < 1 1.6 m MPE 10,000 CMa, EBRTa 3+ > 90
5 Surgical resection (LN) 30,000 NT 1+ 15 3 d MPE 56,000 NT 2+ 70
6 MPE 320 CM 1+ 20 0 d Pleural biopsy 240 CM 2+ 70
7 MPE 5000 NT 2+ 50 0 d Surgical resection (LN) 10,000 NT 2+ 5
8 MPE 6000 NT 2+ 55 0 d Endobronchial FB 450 NT 1+ 15
9 MPE 150,000 NT 3+ > 90 1 d Endobronchial FB 234,000 NT 1+ 10
10 MPE 80,000 NT 3+ > 90 2 d CTG-CN (lung) 37,100 NT 2+ 20
11 MPE 500 NT 3+ > 90 2 d Endobronchial FB 400 NT 1+ 40
12 MPE 30,000 NT 3+ > 90 4 d Pleural biopsy 1060 NT 2+ 35
13 MPE 125 NT 2+ 20 6 d Pleural biopsy 450 NT 1+ < 1
14 MPE 10,000 NT 3+ 90 10 d Lymph node biopsy 550 NT 1+ 2
15 MPE 1540 NT 1+ 20 19.1 m Pleural biopsy 4520 TGTa 1+ < 1
  1. Abbreviation: VTC viable tumor cells, MPE malignant pleural effusion from thoracentesis, PD-L1 programmed cell death ligand-1, CTG-CN computed tomography-guided core needle biopsy, FB forceps biopsy, NT no treatment, CM chemotherapy, TGT targeted therapy, AIT adoptive cellular immunotherapy, EBRT external beam radiotherapy; adifferent from previous treatments; Specimen 1 obtained earlier than specimen 2